ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

lumacaftor

Also written as “LUM/IVA”, “Lumacaftor” and “VX-809”.

Its studies are mostly in Cystic Fibrosis · Cognitive Dysfunction, led by 3 companies.

Drug pageLumacaftor: every studyAll 24 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 4, since Aug 15, 201623 company-led studies, 1 open or runningNext primary completion: May 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Vertex Pharmaceuticals210 open or runningphase 4since Aug 15, 2016Mar 18, 2009none ahead
Qanatpharmaits history only11 open or runningphase 2since May 5, 2025May 5, 2025May 2027phase 2 · NCT07695090
Qanatpharma Canadaits history only10 open or runningphase 1since Jul 21, 2023Jul 21, 2023none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Vertex Pharmaceuticals only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 5 studies since Mar 18, 2009.

  1. Mar 4, 20132 phase 3 studies in Cystic FibrosisNCT01807949, NCT01807923
  2. Jun 20, 2013Phase 1 study in Hepatic ImpairmentNCT01888393 · 23 enrolled · Czech Republic, Slovakia
  3. Jul 8, 2013Phase 3 study in Cystic FibrosisNCT01897233 · 62 enrolled · United States, Canada
  4. Jul 10, 20132 phase 1 studies in Cystic FibrosisNCT01899105, NCT01910415
  5. Aug 26, 2013Phase 3 study in Cystic FibrosisNCT01931839 · 1,164 enrolled · United States, Australia, Austria and more
  6. Mar 11, 2015Phase 3 study in Cystic FibrosisNCT02390219 · 46 enrolled · United States
  7. Jul 23, 2015Phase 3 study in Cystic FibrosisNCT02514473 · 206 enrolled · United States, Australia, Belgium and more
  8. Sep 1, 2015Phase 3 study in Cystic FibrosisNCT02544451 · 246 enrolled · United States, Australia, Belgium and more
  9. Aug 15, 2016Phase 4 study in Cystic FibrosisNCT02875366 · 70 enrolled · Australia, United Kingdom
  10. Feb 9, 2017Phase 2 study in Cystic FibrosisNCT03061331 · 20 enrolled · Netherlands
  11. Apr 19, 2017Phase 3 study in Cystic FibrosisNCT03125395 · 57 enrolled · United States, Canada
  12. Jul 18, 2018Phase 3 study in Cystic FibrosisNCT03601637 · 61 enrolled · United States, Canada
  13. Aug 7, 2018Phase 2 study in Cystic FibrosisNCT03625466 · 51 enrolled · Germany
  14. Jan 15, 2020Phase 3 study in Cystic FibrosisNCT04235140 · 52 enrolled · United States, Canada

TargetBeta

CFTR →read by rule
“Cystic fibrosis transmembrane conductance regulator stabiliser”ChEMBL 37, by rule

Other programs on CFTR

ProgramCompanyFurthest phaseStudies
ivacaftorruleVertex Pharmaceuticalsphase 478
tezacaftorruleVertex Pharmaceuticalsphase 339

Studies

All 21 Vertex Pharmaceuticals leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT04235140Cystic Fibrosis · United States, Canada3CompletedAug 22, 202352
NCT03625466Cystic Fibrosis · Germany2CompletedOct 9, 202051
NCT03601637Cystic Fibrosis · United States, Canada3CompletedOct 29, 202161
NCT03125395Cystic Fibrosis · United States, Canada3CompletedJul 17, 201957
NCT03061331Cystic Fibrosis · Netherlands2CompletedSep 6, 201720
NCT02875366Cystic Fibrosis · Australia, United Kingdom4CompletedSep 201770
NCT02544451Cystic Fibrosis · United States, Australia, Belgium and more3CompletedAug 2018246
NCT02514473Cystic Fibrosis · United States, Australia, Belgium and more3CompletedSep 2016206
NCT02390219Cystic Fibrosis · United States3CompletedOct 201646
NCT01931839Cystic Fibrosis · United States, Australia, Austria and more3CompletedApr 20161,164
NCT01910415Cystic Fibrosis · Netherlands1CompletedMar 2014200
NCT01899105Cystic Fibrosis · United States1CompletedAug 201328
NCT01897233Cystic Fibrosis · United States, Canada3CompletedOct 201562
NCT01888393Hepatic Impairment · Czech Republic, Slovakia1CompletedNov 201323
NCT01807949Cystic Fibrosis · United States, Australia, Austria and more3CompletedApr 2014563
NCT01807923Cystic Fibrosis · United States, Australia, Canada and more3CompletedApr 2014559
NCT01768663Cystic Fibrosis · United States1CompletedSep 201380
NCT01225211Cystic Fibrosis · United States, Australia, Belgium and more2CompletedApr 2014312
NCT01216046Cystic Fibrosis · United States1CompletedMay 201148
NCT00966602Cystic Fibrosis · Netherlands1CompletedDec 200924
NCT00865904Cystic Fibrosis · United States, Belgium, Canada and more2CompletedDec 200993

How it is read

Names in the registry

  • “LUM/IVA”, 8 entries
  • “Lumacaftor”, 5 entries
  • “VX-809”, 4 entries
  • “Lumacaftor Plus Ivacaftor Combination”, 3 entries
  • “Lumacaftor 200 MG”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.